atrial fibrillation

Comprehensive Review in The Lancet Explores Atrial Fibrillation Risk Factors and Management

(IN BRIEF) A recent comprehensive review published in The Lancet Regional Health Europe offers insights into the risk factors and…

2 months ago

EHRA 2023: Celebrating 20 Years of Advancements in Arrhythmia Management

(IN BRIEF) The EHRA 2023 scientific congress of the European Heart Rhythm Association (EHRA), a branch of the European Society…

1 year ago

Boehringer Ingelheim released two GLORIA™-AF Registry Program analyses examining the use of anticoagulant treatments for stroke prevention in patients with atrial fibrillation

For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in…

9 years ago

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating…

10 years ago

Professor Paulus Kirchhof at ESC Congress 2013: Personalised management to close mortality gap for patients with atrial fibrillation (AF)

27-8-2013 — /EuropaWire/ — The fourth AFNET/EHRA consensus conference was convened to discuss how to identify the underlying main pathophysiologies of AF…

11 years ago

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the…